<DOC>
	<DOCNO>NCT01106508</DOCNO>
	<brief_summary>This first-in-human dose-escalation study characterize safety , tolerability , pharmacokinetics pharmacodynamics LEQ506 give orally daily dose schedule patient advance solid tumor .</brief_summary>
	<brief_title>A Dose Finding Safety Study Oral LEQ506 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>Confirmed diagnosis advance solid tumor , recurrent refractory medulloblastoma locally advance metastatic basal cell carcinoma ) Protocol define laboratory parameter Performance status â‰¤ 2 Patients must fully recover prior effect major surgery acute toxicity prior chemotherapy/radiotherapy History central nervous system tumor symptomatic brain metastasis ( excludes medulloblastoma patient ) Impairment gastrointestinal function unresolved nausea , vomit diarrhea Impairment cardiac function significant cardiac disease Pregnant lactate woman Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Advanced solid tumor</keyword>
	<keyword>recurrent refractory medulloblastoma</keyword>
	<keyword>locally advanced metastatic basal cell carcinoma</keyword>
	<keyword>hedgehog pathway inhibitor</keyword>
</DOC>